Bb Healthcare Share Discussion Threads

[speedsgh] 09/4/2021 15:31

Citywire podcast (40m31s). Transcript of podcast also available lower down the page on the following link... Covid-19: What does the future of vaccination look like now? - HTTPS://citywire.co.uk/investment-trust-insider/news/covid-19-what-does-the-future-of-vaccination-look-like-now/a1492042 Citywire’s Gavin Lumsden talks to Paul Major, fund manager of BB Healthcare (BBH) investment trust; Dr Annalisa Jenkins, former chief executive of Dimension Therapeutics; and Professor Justin Stebbing, professor of cancer medicine and oncology at Imperial College London and a non-executive director of BBH, about the scientific, political and societal challenges in keeping coronavirus at bay. This is the second in a series of three Funds Fanatic podcasts in association with BB Healthcare. The first looked at the ‘global collaboration that will help us defeat Covid-19’ - HTTPS://citywire.co.uk/investment-trust-insider/news/the-global-collaboration-that-will-help-us-defeat-covid-19/a1428246?section=investment-trust-insider&linkSource=article-body

[pob69] 10/3/2021 10:35

Interesting blog post hTTps://www.itinvestor.co.uk/2021/03/bb-healthcare-trust-curing-the-health-system/

[jonwig] 08/7/2020 07:07

Always an entertaining and instructive read! They seem to enjoy writing their reports, unlike the dry-as-dust stuff you usually see.

[rambutan2] 08/7/2020 03:41

Yes, it did make it into the 250, and continues to grow with 461,750,000 shares now in issue. June fact sheet: htTps://www.rns-pdf.londonstockexchange.com/rns/1638S_1-2020-7-6.pdf

[rambutan2] 18/5/2020 03:41

Just realised that this is headed for a spot in the FTSE 250 at the June 3 review.

[jonwig] 26/3/2019 06:47

Citywire on management changes: Https://citywire.co.uk/investment-trust-insider/news/star-bb-biotech-manager-steps-back-from-healthcare-trust/a1214097?ref=investment-trust-insider-latest-news-list

[jonwig] 06/11/2018 08:50

Thankls Eberhardt - if you register you get two free articles a week (that's good enough for me usually: BB Healthcare Trust reckons last month’s market sell-off is too much of an opportunity to miss. The investment trust pressed ahead with a share issue programme yesterday that could mean it raises more than its current market value over the next 12 months. It argued that the October fall in prices had a disproportionately high effect on the kinds of smaller, high-growth companies it invests in and there are stockpicking deals to be had. BB Healthcare may actually be one itself. Its shares have lost 9 per cent since the beginning of October, against a drop of 4.5 per cent in the wider MSCI Healthcare index that it benchmarks itself against. The company is worth a closer look. BB Healthcare was listed in December 2016 and is managed by Bellevue Asset Management, a Swiss-based group that came up with the idea of a specialist healthcare investment trust after it encountered investment constraints with an existing, much larger biotech fund. Its brief is to invest in listed healthcare companies worldwide based on no criteria other than potential future value. It has limited itself to a maximum of 35 holdings and in practice 94 per cent of its portfolio is with American companies, hardly surprising given the entrepreneurial role of the private sector in healthcare provision with a regulator that is keen to foster innovation in treatments. Among its largest investments is Anthem, a health insurance company formerly known as Wellpoint; Teladoc, a phone-based healthcare provider; and Illumina, a technology-driven group whose products are used in genetic analysis. The fund tries to ensure all of its funds are invested at any one time but regularly issues new stock to fund growth, unafraid to quadruple its size in the coming years from its current £430 million. Its facility yesterday authorised it to issue as many as 345 million new shares over the next 12 months, worth a little more than £470 million, based on yesterday’s price, up 1p to 135½p. Its strategy of investing in huge structural changes in worldwide health provision against the backdrop of our longer lives, better treatments for chronic diseases and the rise of private care is interesting. ADVICE Buy for the long term WHY Proven in profiting from healthcare’s structural changes

[eberhardt] 06/11/2018 08:35

According Tempus in The Times today BBH is a buy for the long term. Not a subscriber so can't give full link. Reported in the news summary in Citywire hxxps://citywire.co.uk/money/tuesday-papers-brussels-to-offer-border-compromise/a1172662?ref=citywire-money-latest-news-list

[jonwig] 05/11/2018 07:09

Issue of equity, including placing, open offer, intermediaries offer: https://www.investegate.co.uk/bb-healthcare-trust--bbh-/rns/issue-of-equity/201811050700052672G/ "The issue price per Ordinary Share of any shares issued pursuant to the Initial Issue will be at a premium of 2% to the unaudited NAV per Ordinary Share (cum income) on the day that the Initial Placing closes, which is expected to be 28 November 2018. "

[jonwig] 28/8/2018 10:10

Woodford's mistake was taking big stakes in small companies, then getting stuck and unable to unload his losers. His stock-picking skills are poor, though.

[semper vigilans] 28/8/2018 09:55

At the moment.....?

[toffeeman] 28/8/2018 09:52

they are too small for BBH

[semper vigilans] 28/8/2018 09:09

Would be good for all concerned if BBH invested in AGL & AOR if it hasn’t done so already. Performance v. good anyway!

[jonwig] 11/5/2018 20:09

FT maybe explains recent strength: Ater a brief wobble, drug stocks are moving broadly higher on Friday as US President Donald Trump unveiled plans to keep a lid on rising prices, primarily by targeting foreign countries he claims have been freeloading off American research and development. Among the movers: • The S&P 500 healthcare sector is now up 1.2 per cent after briefly dipping into negative territory at the start of the speech. • Pharmacy chain CVS is up 1.7 per cent, and Walgreens is up 0.2 per cent. • Healthcare services company Cardinal Health is up 1.17 per cent, McKesson is up 1.7 per cent, Express Scripts is up 2.86 per cent and AmerisourceBergen is up 1.87 per cent • Drugmaker AbbVie is up 1.13 per cent, Pfizer is up 1.3 per cent, Merck is up 2.26 per cent, Bristol-Myers Squibb is up 1.17 per cent • The Nasdaq biotechnology index is up 2.2 per cent, and biotech company Regeneron is up 7 per cent.

[jonwig] 09/4/2018 13:51

Factsheet out. Problems? Politics, mainly!

[jonwig] 04/4/2018 06:42

@ Toffee - dunno: March factsheet is due any day now. US markets aren't looking good.

[toffeeman] 03/4/2018 20:54

Now trading below Nav (for the first time I think).Someat oop?

[jonwig] 16/2/2018 06:54

Comment on BBH after the annual results: Http://citywire.co.uk/investment-trust-insider/news/bb-healthcare-relieved-us-reforms-off-republican-agenda/a1092177?ref=investment-trust-insider-latest-news-list Maybe answers your question, Toffeeman!

[toffeeman] 01/2/2018 16:23

Bit of a grim few days - is this pre-bear market?

[jonwig] 24/10/2017 06:24

BBH a part of this article: Http://citywire.co.uk/investment-trust-insider/news/james-carthew-don-t-let-biopharma-s-slow-start-give-you-the-wrong-impression/a1061739?ref=investment-trust-insider-latest-news-list

[jonwig] 21/9/2017 07:10

Result of issue: 57,224,047 new shares at 112.1p.

[jonwig] 20/9/2017 11:37

We have an up-to-date NAV for last night: 110.48p, so issue price should be 112.14p.

[jonwig] 20/9/2017 10:00

Interview: Http://citywire.co.uk/investment-trust-insider/news/beware-dividend-dangers-warns-bb-healthcare/a1050407?ref=investment-trust-insider-latest-news-list

[jonwig] 19/9/2017 07:39

Latest NAV 111p so new shares would notionally be offered at ~112.7p. But if NAV fall is due to USD, it could continue and the offer overtaken by events. Can probably wait until noon tomorrow as unlikely to be over-subscribed, I think. Issue price is determined as cum-inc NAV at today's close plus 1.5%. Unfortunately that won't be published until mid-afternoon tomorrow, so best estimate is yesterday's closing NAV to be published this afternoon.